Compugen Reports Second Quarter 2024 Results PR Newswire HOLON, Israel, Aug. 6, 2024 FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire HOLON, Israel, July 29, 2024 FDA clearance triggers a $30 million milestone payment...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel, July 23, 2024 HOLON, Israel, July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel, June 17, 2024 HOLON, Israel, June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a...
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire HOLON, Israel, May 30, 2024 Phase 3 trial evaluating...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.59 | -1.46985550573 | 40.14 | 40.3 | 33.13 | 2282 | 37.07621844 | CS |
4 | 3.74 | 10.4440100531 | 35.81 | 42.44 | 33.13 | 2089 | 37.16474028 | CS |
12 | 3.65 | 10.1671309192 | 35.9 | 42.44 | 32.84 | 9570 | 34.61323183 | CS |
26 | 7.4 | 23.0171073095 | 32.15 | 42.44 | 28.22 | 16212 | 31.84797628 | CS |
52 | 10.58 | 36.5205384881 | 28.97 | 42.44 | 23.45 | 12756 | 30.49035963 | CS |
156 | 20.94 | 112.520150457 | 18.61 | 42.44 | 17.61 | 8474 | 29.3161492 | CS |
260 | -28.327 | -41.7328402846 | 67.877 | 95.96 | 17.61 | 6455 | 30.86251565 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.